Kelly Lawrence W & Associates Inc. CA Purchases Shares of 332,275 Hims & Hers Health, Inc. $HIMS

Key Points

• Kelly Lawrence W & Associates purchased 332,275 shares of Hims & Hers Health worth approximately $11.52 million, making the stock its 16th-largest portfolio holding and representing about 0.14% of HIMS.
• Institutional ownership remains substantial at 63.52%, with major investors including Vanguard, Bank of America, Invesco and Marex increasing their positions.
• HIMS was trading at $31.07 after an 8% decline; the company reported revenue of $753.21 million, up 38.2% year over year, but missed earnings expectations with a loss of $0.37 per share. Analysts’ consensus rating is Hold, with an average price target of $32.50.

Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 332,275 shares of the company's stock, valued at approximately $11,520,000. Hims & Hers Health comprises about 2.5% of Kelly Lawrence W & Associates Inc. CA's portfolio, making the stock its 16th biggest position. Kelly Lawrence W & Associates Inc. CA owned about 0.14% of Hims & Hers Health at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Bank of America Corp DE lifted its stake in shares of Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock valued at $90,465,000 after purchasing an additional 2,877,550 shares in the last quarter. Norges Bank acquired a new stake in Hims & Hers Health during the 4th quarter worth approximately $62,153,000. Invesco Ltd. increased its position in Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company's stock worth $235,525,000 after purchasing an additional 1,600,004 shares in the last quarter. Marex Group plc lifted its position in Hims & Hers Health by 162.2% during the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company's stock valued at $78,562,000 after buying an additional 1,496,707 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company's stock worth $679,456,000 after buying an additional 1,407,651 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Trading Down 8.0%

HIMS opened at $31.07 on Tuesday. The firm has a market capitalization of $7.25 billion, a P/E ratio of -49.33 and a beta of 2.40. The firm's 50 day moving average is $32.39 and its 200-day moving average is $26.18. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $65.30. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analysts' expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health's revenue for the quarter was up 38.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. Analysts expect that Hims & Hers Health, Inc. will post -0.14 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the company's stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares of the company's stock, valued at $13,611,906. This represents a 3.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 55,383 shares of the firm's stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47. Following the sale, the chief financial officer owned 228,938 shares of the company's stock, valued at $8,033,434.42. This represents a 19.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 186,769 shares of company stock worth $6,035,648 over the last three months. Insiders own 11.76% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HIMS. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a report on Friday, May 22nd. Wall Street Zen raised shares of Hims & Hers Health from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Zacks Research upgraded Hims & Hers Health from a "strong sell" rating to a "hold" rating in a report on Monday, July 13th. Finally, Barclays cut their price objective on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a research report on Friday. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $32.50.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source